Perspectives of proteomics in acute myeloid leukemia

Expert Review of Anticancer Therapy

Volumn 6, Issue 11, 2006, Pages 1663-1675

  Czibere, Akos ^a,b   Grall, Franck ^b   Aivado, Manuel ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Biomarkers; Protein mass spectrometry; Protein profiling proteomics

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALKYLATING AGENT; AZACITIDINE; BENZENE; BEVACIZUMAB; BIOLOGICAL MARKER; CYTOTOXIC AGENT; ETOPOSIDE; GYRASE INHIBITOR; IFOSFAMIDE; RITUXIMAB; VALPROIC ACID;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; CAPILLARY ELECTROPHORESIS; COLORECTAL CANCER; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ELECTROSPRAY MASS SPECTROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOMICS; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HODGKIN DISEASE; HUMAN; LEUKEMIA RELAPSE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MORTALITY; OVERALL SURVIVAL; PATIENT CARE; PROGNOSIS; PROTEIN ANALYSIS; PROTEOMICS; REPRODUCIBILITY; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURVIVAL RATE; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; NEOPLASM PROTEINS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33845459900     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.11.1663     Document Type: Review

References (99)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N. Engl. J. Med. 341, 1051-1062 (1999).
2. Seiter K. Toxicity of the topoisomerase II inhibitors. Expert Opin. Drug Saf. 4, 219-234 (2005).
3. Wierecky J, Kollmannsberger C, Boehlke I et al. Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J. Cancer Res. Clin. Oncol. 131, 255-260 (2005).
4. Koschmieder S, Rosenbauer F, Steidl U, Owens BM, Tenen DG. Role of transcription factors C/EBPα and PU. 1 in normal hematopoiesis and leukemia. Int. J. Hematol. 81, 368-377 (2005).
5. Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. Effect of transcription-factor concentrations on leukemic stem cells. Blood 106, 1519-1524 (2005).
6. Rosenbauer F, Owens BM, Yu L et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU. 1. Nat. Genet. 38, 27-37 (2006).
7. Jabbour EJ, Estey E, Kantarjian HM. Adult acute myeloid leukemia. Mayo Clin. Proc. 81, 247-260 (2006).
8. Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann. Intern. Med. 103, 620-625 (1985).
9. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting- Airlie House, Virginia, November 1997. J. Clin. Oncol. 17, 3835-3849 (1999).
10. Burnett AK, Eden OB. The treatment of acute leukaemia. Lancet 349, 270-275 (1997).
11. Farag SS, Archer KJ, Mrozek K et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 108, 63-73 (2006).
12. Grimwade D, Walker H, Oliver F et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92, 2322-2333 (1998).
13. Nakao M, Yokota S, Iwai T et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10, 1911-1198 (1996).
14. Tanner SM, Austin JL, Leone G et al. BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc. Natl Acad. Sci. USA 98, 13901-13906 (2001).
15. Pabst T, Mueller BU, Zhang P et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat. Genet. 27, 263-270 (2001).
16. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood (2006) (Epub ahead of print).
17. Bullinger L, Dohner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350, 1605-1616 (2004).
18. Schmid C, Schleuning M, Schwerdtfeger R et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 108, 1092-1099 (2006).
19. Aoudjhane M, Labopin M, Gorin NC et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from-the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19, 2304-2312 (2005).
20. Schmitz N, Bacigalupo A, Labopin M et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br. J. Haematol. 95, 715-723 (1996).
21. Tallman MS, Andersen JW, Schiffer CA et al. All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337, 1021-1028 (1997).
22. Kritz AD, Raptis G, Menendez-Botet C, Maslak P, Jakubowski A. Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia. Am. J. Hematol. 51, 117-121 (1996).
23. Maslak P, Chanel S, Camacho, LH et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20, 212-217 (2006).
24. Issa JP, Garcia-Manero G, Giles FJ et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103, 1635-1640 (2004).
25. Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 106, 112-119 (2006).
26. Simon R, Radmacher MD, Dobbin K, McShane M. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J. Natl Cancer Inst. 95, 14-18 (2003).
27. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat. Rev. Cancer 4, 309-14 (2004).
28. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19, 1720-1730 (1999).
29. Ideker T, Thorsson V, Ranish JA et al. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292, 929-934 (2001).
30. Thadikkaran L, Siegenthaler MA, Crettaz D, Queloz PA, Schneider P, Tissot JD. Recent advances in blood-related proteomics. Proteomics 5, 3019-3034 (2005).
31. Zheng PZ, Wang KK, Zhang QY et al. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/ apoptosis of promyelocytic leukemia. Proc. Natl Acad. Sci. USA 102, 7653-7658 (2005).
32. Juan HF, Lin JY, Chang WH et al. Biomic study of human myeloid leukemia cells differentiation to macrophages using DNA array, proteomic, and bioinformatic analytical methods. Electrophoresis 23, 2490-2504 (2002).
33. Engel E, Jenkins DE Jr, Tipton RE, McGee BJ, Engel-de Montmollin M. PH1-positive chronic myelogenous leukemia, with absence of another G chromosome, in a male. N. Engl. J. Med. 273, 738-742 (1965).
34. Cools J, DeAngelo DJ, Gotlib J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348, 1201-1214 (2003).
35. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Ab1 positive cells. Nat. Med. 2, 561-566 (1996).
36. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. IDEC-C2B8: results of a Phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J. Clin. Oncol. 15, 3266-3274 (1997).
37. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60-65 (2003).
38. Schindler J, Nothwang HG. Aqueous polymer two-phase systems: effective tools for plasma membrane proteomics. Proteomics 6(20), 5409-5417 (2006).
39. Boyd RS, Adam PJ, Patel S et al. Proteomic analysis of the cell-surface membrane in chronic lymphocytic leukemia: identification of two novel proteins, BCNP1 and MIG2B. Leukemia 17, 1605-1612 (2003).
40. Ruth MC, Old WM, Emrick MA et al. Analysis of membrane proteins from human chronic myelogenous leukemia cells: comparison of extraction methods for multidimensional LC-MS/MS. J. Proteome Res. 5, 709-719 (2006).
41. Petti MC, Mandelli F, Zagonel V et al. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7 (Suppl. 1), 36-41 (1993).
42. Ng PW, Porter AG, Janicke RU. Molecular cloning and characterization of two novel pro-apoptotic isoforms of caspase-10. J. Biol. Chem. 274, 10301-10308 (1999).
43. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 1, 845-867 (2002).
44. Huang L, Harvie G, Feitelson JS et al. Immunoaffinity separation of plasma proteins by IgY microbeads: meeting the needs of proteomic sample preparation and analysis. Proteomicr 5, 3314-3328 (2005).
45. Pitarch A, Abian J, Carrascal M, Sanchez M, Nombela C, Gil C. Proteomics-based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. Proteomics 4, 3084-3106 (2004).
46. Kaiser T, Kamal H, Rank A et al. Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 104, 340-349 (2004).
47. Nensen N, Haaland I, D'Santos C, Van Belle W, Gjertse BT. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Curr. Pharm. Biotechnol. 7, 199-207 (2006).
48. Balkhi MY, Trivedi AK, Geletu M et al. Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications. Oncogene 25(53), 7041-7058 (2006).
49. Fenn JB, Mann M, Meng CK, Wong SF, Whitehouse CM. Electrospray ionization for mass spectrometry of large biomolecules. Science 246, 64-71 (1989).
50. Tanaka K, Ii K, Ichihara A, Waxman L, Goldberg AL. A high molecular weight protease in the cytosol of rat liver. Purification, enzymological properties, and tissue distribution. J. Biol. Chem. 261, 15197-15203 (1986).
51. Hillenkamp F, Karas M. Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol. 193, 280-295 (1990).
52. Marshall AG, Hendrickson CL, Jackson GS. Fourier transform ion cyclotron resonance mass spectrometry: a primer. Mass Spectrom. Rev. 17, 1-35 (1998).
53. Olthoff JK, Lys IA, Cotter RJ. A pulsed time-of-flight mass spectrometer for liquid secondary ion mass spectrometry. Rapid Comm. Mass Spectrom. 2, 171-175 (1988).
54. Aebersoid R, Mann M. Mass spectrometry-based proteomics. Nature 422, 198-207 (2003).
55. Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc. Natl Acad. Sci. USA 90, 5011-5015 (1993).
56. Medzihradszky KF. Peptide sequence analysis. Methods Enzymol. 402, 209-244 (2005).
57. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. Probability-based protein Identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567 (1999).
58. Havilio M, Haddad Y, Smilansky Z. Intensity-based statistical scorer for tandem mass spectrometry. Anal. Chem. 75, 435-444 (2003).
59. Hanash S. Disease proteomics. Nature 422, 226-232 (2003).
60. Gorg A, Weiss W, Dunn MJ. Current two-dimensional electrophoresis technology for proteomics. Proteomics 4, 3665-3685 (2004).
61. Marengo E, Robotti E, Righetti PG et al. Study of proteomic changes associated with healthy and tumoral murine samples in neuroblastoma by principal component analysis and classification methods. Clin. Chim. Acta 345, 55-67 (2004).
62. Alban A, David SO, Bjorkesten L et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3, 36-44 (2003).
63. Joubert-Caron R, Caron M. Proteome analysis in the study of lymphoma cells. Mass Spectrom. Rev. 24, 455-468 (2005).
64. Hanash SM, Baler LJ. Two-dimensional gel electrophoresis of cellular proteins reveals myeloid origin of blasts in two children with otherwise undifferentiated leukemia. Cancer 57, 1539-1543 (1986).
65. Hanash SM, Baier LJ, McCurry L, Schwartz SA. Lineage-related polypeptide markers in acute lymphoblastic leukemia detected by two-dimensional gel electrophoresis. Proc. Natl Acad. Sci. USA 83, 807-811 (1986).
66. Hanash SM, Madoz-Gurpide J, Misek DE. Identification of novel targets for cancer therapy using expression proteomics. Leukemia 16, 478-485 (2002).
67. Hanash SM, Kuick R, Strahler J et al. Identification of a cellular polypeptide that distinguishes between acute lymphoblastic leukemia in infants and in older children. Blood 73, 527-532 (1989).
68. Kwak JY, Ma TZ, Yoo MJ et al. The comparative analysis of serum proteomes for the discovery of biomarkers for acute myeloid leukemia. Exp. Hematol. 32, 836-842 (2004).
69. Melhem RF, Zhu XX, Hailat N, Strahler JR, Hanash SM. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J. Biol. Chem. 266, 17747-17753 (1991).
70. Nishio K, Nakamura T, Koh Y, Kanzawa F, Tamura T, Saijo N. Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells. Cancer 91, 1494-1499 (2001).
71. Liotta L, Petricoin E. Molecular profiling of human cancer. Nat. Rev. Genet. 1, 48-56 (2000).
72. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Comm. Mass Spectrom. 7, 576-580 (1993).
73. Aivado M, Spentzos D, Alterovitz G et al. Optimization and evaluation of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOFMS) with reversed-phase protein arrays for protein profiling. Clin. Chem. Lab. Med. 43, 133-140 (2005).
74. Zhang Z, Bast RC Jr, Yu Y et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64, 5882-5890 (2004).
75. Smith MT, McHale CM, Wiemels JL et al. Molecular biomarkers for the study of childhood leukemia. Toxicol. Appl. Pharmacol. 206, 237-245 (2005).
76. Sheng S, Chen D, Van Eyk JE. Multidimensional liquid chromatography separation of intact proteins by chromatographic focusing and reversed phase of the human serum proteome: optimization and protein database. Mol. Cell. Proteomics 5, 26-34 (2006).
77. Wang Y, Hancock WS, Weber G, Eckerskorn C, Palmer-Toy D. Free flow electrophoresis coupled with liquid chromatography-mass spectrometry for a proteomic study of the human cell line (K562/CR3). J. Chromatogr. A. 1053, 269-278 (2004).
78. Kelleher NL. Top-down proteomics. Anal. Chem. 76, A197-A203 (2004).
79. Yaneva M, Tempst P. Affinity capture of specific DNA-binding proteins for mass spectrometric identification. Anal. Chem. 75, 6437-6448 (2003).
80. Zheng H, Hu P, Quinn DF, Wang YK. Phosphotyrosine proteomic study of interferon α signaling pathway using a combination of immunoprecipitation and immobilized metal affinity chromatography. Mol. Cell. Proteomics 4, 721-730 (2005).
81. Irish JM, Hovland R, Krutzik PO et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118, 217-228 (2004).
82. Florens L, Washburn MP. Proteomic analysis by multidimensional protein identification technology. Methods Mol. Biol. 328, 159-175 (2006).
83. Paoletti AC, Zybailov B, Washburn MP. Principles and applications of multidimensional protein identification technology. Expert Rev. Proteomics 1, 275-282 (2004).
84. Wang W, Zhou H, Lin H et al. Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. Anal. Chem. 75, 4818-4826 (2003).
85. Ong SE, Blagoev B, Kratchmarova I et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386 (2002).
86. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999 (1999).
87. Han DK, Eng J, Zhou H, Aebersold R. Quantitative profiling of differentiation-induced microsomal proteins using isotope-coded affinity tags and mass spectrometry. Nat. Biotechnol. 19, 946-951 (2001).
88. Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3, 1154-1169 (2004).
89. Unwin RD, Smith DL, Blinco D et al. Quantitative proteomics reveals posttranslational control as a regulatory factor in primary hematopoietic stem cells. Blood 107, 4687-4694 (2006).
90. Chatterjee SK, Zetter BR. Cancer biomarkers: knowing the present and predicting the future. Future Oncol. 1, 37-50 (2005).
91. Kashyap MK, Kumar A, Emelianenko N et al. Biochemical and molecular markers in renal cell carcinoma: an update and future prospects. Biomarkers 10, 258-294 (2005).
92. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 5, 845-856 (2005).
93. Wilkins MR, Appel RD, Van Eyk JE et al. Guidelines for the next 10 years of proteomics. Proteomics 6, 4-8 (2006).
94. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin. Chem. 52, 1284-1293 (2006).
95. Nielsen UB, Cardone MH, Sinskey AJ, MacBeath G, Sorger PK. Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc. Natl Acad. Sci. USA 100, 9330-9335 (2003).
96. Hudelist G, Pacher-Zavisin M, Singer CF et al. Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue. Breast Cancer Res. Treat. 86, 281-291 (2004).
97. Christopherson RI, Stoner K, Barber N et al. Classification of AML using a monoclonal antibody microarray. Methods Mol. Med. 125, 241-251 (2006).
98. Kuhn E, Wu J, Karl J, Liao H, Zolg W, Guild B. Quantification of C-reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled peptide standards. Proteomics 4, 1175-1186 (2004).
99. Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3, 235-244 (2004).